Antibodies to the superantigenic site of HIV-1 gp120: Hydrolytic and binding activities of the light chain subunit

Molecular Immunology

Volumn 44, Issue 10, 2007, Pages 2707-2718

  Nishiyama, Yasuhiro ^a   Karle, Sangeeta ^a   Planque, Stephanie ^a   Taguchi, Hiroaki ^a   Paul, Sudhir ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

B cell superantigen; Catalytic antibody light chain; HIV gp120; Lupus; Phage library

Indexed keywords

ANTIBODY; DRUG RESIDUE; GLYCOPROTEIN GP 120; PEPTIDE; PROTEIN;

ACYLATION; ARTICLE; BINDING AFFINITY; DEACYLATION; FRACTIONATION; HEAVY CHAIN; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HYDROLYSIS; LIGHT CHAIN; LUPUS VULGARIS; MOLECULAR RECOGNITION; OBSERVATION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN ISOLATION;

AMINO ACID SEQUENCE; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; CATALYSIS; HAPTENS; HIV ENVELOPE PROTEIN GP120; HUMANS; HYDROLYSIS; IMMUNOGLOBULIN LIGHT CHAINS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MOLECULAR SEQUENCE DATA; PEPTIDE LIBRARY; SUPERANTIGENS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33846903835     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.molimm.2006.12.005     Document Type: Article

References (67)

1. Berberian L., Valles-Ayoub Y., Sun N., Martinez-Maza O., and Braun J. A VH clonal deficit in human immunodeficiency virus-positive individuals reflects a B-cell maturational arrest. Blood 78 (1991) 175-179
2. Berberian L., Goodglick L., Kipps T.J., and Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 261 (1993) 1588-1591
3. Berisha H.I., Bratut M., Bangale Y., Colasurdo G., Paul S., and Said S.I. New evidence for transmitter role of VIP in the airways: impaired relaxation by a catalytic antibody. Pulm. Pharmacol. Ther. 15 (2002) 121-127
4. Bermas B.L., Petri M., Berzofsky J.A., Waisman A., Shearer G.M., and Mozes E. Binding of glycoprotein 120 and peptides from the HIV-1 envelope by autoantibodies in mice with experimentally induced systemic lupus erythematosus and in patients with the disease. AIDS Res. Hum. Retroviruses 10 (1994) 1071-1077
5. Binley J.M., Wrin T., Korber B., Zwick M.B., Wang M., Chappey C., Stiegler G., Kunert R., Zolla-Pazner S., Katinger H., Petropoulos C.J., and Burton D.R. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78 (2004) 13232-13252
6. Burton D.R., and Montefiori D.C. The antibody response in HIV-1 infection. AIDS 11 Suppl. A (1997) S87-S898
7. Daikh B.E., and Holyst M.M. Lupus-specific autoantibodies in concomitant human immunodeficiency virus and systemic lupus erythematosus: case report and literature review. Semin. Arthritis Rheum. 30 (2001) 418-425
8. DeSilva B.S., Wilson G.S., and Schowen R.L. Catalyst design for reactions with multiple transition states. Chem. Immunol. 77 (2000) 33-57
9. Edelman G.M., Olins D.E., Gally J.A., and Zinder N.D. Reconstitution of immunologic activity by interaction of polypeptide chains of antibodies. Proc. Natl. Acad. Sci. U.S.A. 50 (1963) 753-761
10. Ely K.R., Herron J.N., Harker M., and Edmundson A.B. Three-dimensional structure of a light chain dimer crystallized in water. Conformational flexibility of a molecule in two crystal forms. J. Mol. Biol. 210 (1989) 601-615
11. Fastrez J., and Fersht A.R. Demonstration of the acyl-enzyme mechanism for the hydrolysis of peptides and anilides by chymotrypsin. Biochemistry 12 (1973) 2025-2034
12. Gao Q.S., Sun M., Rees A.R., and Paul S. Site-directed mutagenesis of proteolytic antibody light chain. J. Mol. Biol. 253 (1995) 658-664
13. Goodglick L., Zevit N., Neshat M.S., and Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J. Immunol. 155 (1995) 5151-5159
14. Goodyear C.S., and Silverman G.J. Death by a B cell superantigen: In vivo VH-targeted apoptotic supraclonal B cell deletion by a staphylococcal toxin. J. Exp. Med. 197 (2003) 1125-1139
15. Goodyear C.S., and Silverman G.J. Staphylococcal toxin induced preferential and prolonged in vivo deletion of innate-like B lymphocytes. Proc. Natl. Acad. Sci. U.S.A. 101 (2004) 11392-11397
16. Goodyear C.S., Narita M., and Silverman G.J. In vivo VL-targeted activation-induced apoptotic supraclonal deletion by a microbial B cell toxin. J. Immunol. 172 (2004) 2870-2877
17. Gorny M.K., Xu J.Y., Karwowska S., Buchbinder A., and Zolla-Pazner S. Repertoire of neutralizing human monoclonal antibodies specific for the V3 domain of HIV-1 gp120. J. Immunol. 150 (1993) 635-643
18. Graille M., Stura E.A., Corper A.L., Sutton B.J., Taussig M.J., Charbonnier J.B., and Silverman G.J. Crystal structure of a Staphylococcus aureus protein A domain complexed with the Fab fragment of a human IgM antibody: structural basis for recognition of B-cell receptors and superantigen activity. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 5399-5404
19. Grantham R. Amino acid difference formula to help explain protein evolution. Science 185 (1974) 862-864
20. Haigwood N.L., and Zolla-Pazner S. Humoral immunity to HIV, SIV, and SHIV. AIDS 12 Suppl. A (1998) S121-S132
21. Hartley B.S., and Kilby B.A. The reaction of p-nitrophenyl esters with chymotrypsin and insulin. Biochem. J. 56 (1954) 288-297
22. Hifumi E., Hatiuchi K., Okuda T., Nishizono A., Okamura Y., and Uda T. Specific degradation of H. pylori urease by a catalytic antibody light chain. FEBS J. 272 (2005) 4497-4505
23. Ionescu-Zanetti C., Khurana R., Gillespie J.R., Petrick J.S., Trabachino L.C., Minert L.J., Carter S.A., and Fink A.L. Monitoring the assembly of Ig light-chain amyloid fibrils by atomic force microscopy. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 13175-13179
24. Juompan L., Lambin P., and Zouali M. Selective deficit in antibodies specific for the superantigen binding site of gp120 in HIV infection. FASEB J. 12 (1998) 1473-1480
25. Karle S., Nishiyama Y., Taguchi H., Zhou Y.X., Luo J., Planque S., Hanson C., and Paul S. Carrier-dependent specificity of antibodies to a conserved peptide determinant of gp120. Vaccine 21 (2003) 1213-1218
26. Karle S., Planque S., Nishiyama Y., Taguchi H., Zhou Y.X., Salas M., Lake D., Thiagarajan P., Arnett F., Hanson C.V., and Paul S. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 18 (2004) 329-331
27. Karray S., Juompan L., Maroun R.C., Isenberg D., Silverman G.J., and Zouali M. Structural basis of the gp120 superantigen-binding site on human immunoglobulins. J. Immunol. 161 (1998) 6681-6688
28. Katoh K., Misawa K., Kuma K., and Miyata T. MAFFT: a novel method for rapid multiple sequence alignment based on fast Fourier transform. Nucleic Acids Res. 30 (2002) 3059-3066
29. Katoh K., Kuma K., Toh H., and Miyata T. MAFFT version 5: improvement in accuracy of multiple sequence alignment. Nucleic Acids Res. 33 (2005) 511-518
30. Kwong P.D., Wyatt R., Robinson J., Sweet R.W., Sodroski J., and Hendrickson W.A. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 393 (1998) 648-659
31. Li L., Sun M., Gao Q.S., and Paul S. Low level formation of potent catalytic IgG fragments mediated by disulfide bond instability. Mol. Immunol. 33 (1996) 593-600
32. Li L., Kalaga R., and Paul S. Proteolytic components of serum IgG preparations. Clin. Exp. Immunol. 120 (2000) 261-266
33. Maeda H., Steffen E., and Engel J. Kinetics of dimerization of the Bence-Jones protein Au. Biophys. Chem. 9 (1978) 57-64
34. Matsuura K., Yamamoto K., and Sinohara H. Amidase activity of human Bence Jones proteins. Biochem. Biophys. Res. Commun. 204 (1994) 57-62
35. Mei S., Mody B., Eklund S.H., and Paul S. Vasoactive intestinal peptide hydrolysis by antibody light chains. J. Biol. Chem. 266 (1991) 15571-15574
36. Mitsuda Y., Hifumi E., Tsuruhata K., Fujinami H., Yamamoto N., and Uda T. Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant. Biotechnol. Bioeng. 86 (2004) 217-225
37. Mitsuda Y., Tsuruhata K., Hifumi E., Takagi M., and Uda T. Investigation of active form of catalytic antibody light chain 41S-2-L. Immunol. Lett. 96 (2005) 63-71
38. Neshat M.N., Goodglick L., Lim K., and Braun J. Mapping the B cell superantigen binding site for HIV-1 gp120 on a V(H)3 Ig. Int. Immunol. 12 (2000) 305-312
39. Nishiyama Y., Taguchi H., Luo J.Q., Zhou Y.X., Burr G., Karle S., and Paul S. Covalent reactivity of phosphonate monophenyl esters with serine proteinases: an overlooked feature of presumed transition state analogs. Arch. Biochem. Biophys. 402 (2002) 281-288
40. Nishiyama Y., Bhatia G., Bangale Y., Planque S., Mitsuda Y., Taguchi H., Karle S., and Paul S. Toward selective covalent inactivation of pathogenic antibodies: a phosphate diester analog of vasoactive intestinal peptide that inactivates catalytic autoantibodies. J. Biol. Chem. 279 (2004) 7877-7883
41. Olshevsky U., Helseth E., Furman C., Li J., Haseltine W., and Sodroski J. Identification of individual human immunodeficiency virus type 1 gp120 amino acids important for CD4 receptor binding. J. Virol. 64 (1990) 5701-5707
42. Palacios R., Santos J., Valdivielso P., and Marquez M. Human immunodeficiency virus infection and systemic lupus erythematosus. An unusual case and a review of the literature. Lupus 11 (2002) 60-63
43. Pantophlet R., and Burton D.R. GP120: target for neutralizing HIV-1 antibodies. Annu. Rev. Immunol. 24 (2006) 739-769
44. Paul S. Natural catalytic antibodies. Mol. Biotechnol. 5 (1996) 197-207
45. Paul S., Volle D.J., Powell M.J., and Massey R.J. Site specificity of a catalytic vasoactive intestinal peptide antibody. An inhibitory vasoactive intestinal peptide subsequence distant from the scissile peptide bond. J. Biol. Chem. 265 (1990) 11910-11913
46. Paul S., Li L., Kalaga R., Wilkins-Stevens P., Stevens F.J., and Solomon A. Natural catalytic antibodies: peptide-hydrolyzing activities of Bence Jones proteins and VL fragment. J. Biol. Chem. 270 (1995) 15257-15261
47. Paul S., Tramontano A., Gololobov G., Zhou Y.X., Taguchi H., Karle S., Nishiyama Y., Planque S., and George S. Phosphonate ester probes for proteolytic antibodies. J. Biol. Chem. 276 (2001) 28314-28320
48. Paul S., Planque S., Zhou Y.X., Taguchi H., Bhatia G., Karle S., Hanson C., and Nishiyama Y. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J. Biol. Chem. 278 (2003) 20429-20435
49. Paul S., Karle S., Planque S., Taguchi H., Salas M., Nishiyama Y., Handy B., Hunter R., Edmundson A., and Hanson C. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J. Biol. Chem. 279 (2004) 39611-39619
50. Paul S., Nishiyama Y., Planque S., and Taguchi H. Theory of proteolytic antibody occurrence. Immunol. Lett. 103 (2006) 8-16
51. Planque S., Taguchi H., Burr G., Bhatia G., Karle S., Zhou Y.X., Nishiyama Y., and Paul S. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J. Biol. Chem. 278 (2003) 20436-20443
52. Pollard S.R., Meier W., Chow P., Rosa J.J., and Wiley D.C. CD4-binding regions of human immunodeficiency virus envelope glycoprotein gp120 defined by proteolytic digestion. Proc. Natl. Acad. Sci. U.S.A. 88 (1991) 11320-11324
53. Powers J.C., Asgian J.L., Ekici O.D., and James K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102 (2002) 4639-4750
54. Profy A.T., Salinas P.A., Eckler L.I., Dunlop N.M., Nara P.L., and Putney S.D. Epitopes recognized by the neutralizing antibodies of an HIV-1-infected individual. J. Immunol. 144 (1990) 4641-4647
55. Ramsland P.A., Terzyan S.S., Cloud G., Bourne C.R., Farrugia W., Tribbick G., Geysen H.M., Moomaw C.R., Slaughter C.A., and Edmundson A.B. Crystal structure of a glycosylated Fab from an IgM cryoglobulin with properties of a natural proteolytic antibody. Biochem. J. 395 (2006) 473-481
56. Roholt O., Onoue K., and Pressman D. Specific combination of H and L chains of rabbit gamma-globulins. Proc Natl. Acad. Sci. U.S.A. 51 (1964) 173-178
57. Scamurra R.W., Miller D.J., Dahl L., Abrahamsen M., Kapur V., Wahl S.M., Milner E.C., and Janoff E.N. Impact of HIV-1 infection on VH3 gene repertoire of naive human B cells. J. Immunol. 164 (2000) 5482-5491
58. Sherer Y., Gorstein A., Fritzler M.J., and Shoenfeld Y. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin. Arthritis Rheum. 34 (2004) 501-537
59. Sun M., Li L., Gao Q.S., and Paul S. Antigen recognition by an antibody light chain. J. Biol. Chem. 269 (1994) 734-738
60. Sun M., Gao Q.S., Kirnarskiy L., Rees A., and Paul S. Cleavage specificity of a proteolytic antibody light chain and effects of the heavy chain variable domain. J. Mol. Biol. 271 (1997) 374-385
61. Taguchi H., Burr G., Karle S., Planque S., Zhou Y.X., Paul S., and Nishiyama Y. A mechanism-based probe for gp120-hydrolyzing antibodies. Bioorg. Med. Chem. Lett. 12 (2002) 3167-3170
62. Townsley-Fuchs J., Kam L., Fairhurst R., Gange S.J., Goodglick L., Giorgi J.V., Sidell N., Detels R., and Braun J. Human immunodeficiency virus-1 (HIV-1) gp120 superantigen-binding serum antibodies. A host factor in homosexual HIV-1 transmission. J. Clin. Invest. 98 (1996) 1794-1801
63. Townsley-Fuchs J., Neshat M.S., Margolin D.H., Braun J., and Goodglick L. HIV-1 gp120: a novel viral B cell superantigen. Int. Rev. Immunol. 14 (1997) 325-338
64. Tyutyulkova S., Gao Q.S., Thompson A., Rennard S., and Paul S. Efficient vasoactive intestinal polypeptide hydrolyzing autoantibody light chains selected by phage display. Biochim. Biophys. Acta 1316 (1996) 217-223
65. Urnovitz H.B., and Murphy W.H. Human endogenous retroviruses: nature, occurrence, and clinical implications in human disease. Clin. Microbiol. Rev. 9 (1996) 72-99
66. Zhou Y.X., Karle S., Taguchi H., Planque S., Nishiyama Y., and Paul S. Prospects for immunotherapeutic proteolytic antibodies. J. Immunol. Methods 269 (2002) 257-268
67. Zimmerman M., Ashe B., Yurewicz E.C., and Patel G. Sensitive assays for trypsin, elastase, and chymotrypsin using new fluorogenic substrates. Anal. Biochem. 78 (1977) 47-51